Author:
Wei Huimei,LeSaint Johnathan E.,Jin Zhenyu,Zhan Chang-Guo,Zheng Fang
Abstract
AbstractCocaine dependence is a serious world-wide public health problem without an FDA-approved pharmacotherapy. We recently designed and discovered a highly efficient long-acting cocaine hydrolase CocH5-Fc(M6). The present study examined the effectiveness and duration of CocH5-Fc(M6) in blocking interoceptive effects of cocaine by performing cocaine discrimination tests in rats, demonstrating that the duration of CocH5-Fc(M6) in blocking cocaine discrimination was dependent on cocaine dose and CocH5-Fc(M6) plasma concentration. Particularly, a dose of 3 mg/kg CocH5-Fc(M6) effectively attenuated discriminative stimulus effects of 10 mg/kg cocaine, cumulative doses of 10 and 32 mg/kg cocaine, and cumulative doses of 10, 32 and 56 mg/kg cocaine by ≥ 20% for 41, 19, and 10 days, and completely blocked the discriminative stimulus effects for 30, 13, and 5 days with corresponding threshold plasma CocH5-Fc(M6) concentrations of 15.9, 72.2, and 221 nM, respectively, under which blood cocaine concentration was negligible. Additionally, based on the data obtained, cocaine discrimination model is more sensitive than the locomotor activity to reveal cocaine effects and that CocH5-Fc(M6) itself has no long-term toxicity regarding behavioral activities such as lever pressing and food consumption in rats, further demonstrating that CocH5-Fc(M6) has the desired properties as a promising therapeutic candidate for prevenance of cocaine dependence.
Publisher
Springer Science and Business Media LLC
Reference83 articles.
1. World Drug Report from the United Nations Office on Drugs and Crime; 2021.
2. Vallecillo, G., Perelló, R., Güerri, R., Fonseca, F. & Torrens, M. Clinical impact of COVID-19 on people with substance use disorders. J. Public Health 43(1), 9–12. https://doi.org/10.1093/pubmed/fdaa181 (2020).
3. Wei, Y. & Shah, R. Substance use disorder in the COVID-19 pandemic: A systematic review of vulnerabilities and complications. Pharmaceuticals 13(7), 155 (2020).
4. Avena, N. M., Simkus, J., Lewandowski, A., Gold, M. S. & Potenza, M. N. Substance use disorders and behavioral addictions during the COVID-19 pandemic and COVID-19-related restrictions. Front. Psychiatry 12, 653674. https://doi.org/10.3389/fpsyt.2021.653674 (2021).
5. NIDA. Overdose Death Rates in 2020, https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates.